Abstract: The cooperation of a multidisciplinary team (MDT), which integrates input from different specialties and the concept of evidence-based medicine, offers personalized treatment recommendations that are particularly well-suited for complex individual cases. This study describes the complete MDT diagnosis and treatment process for a patient with extensive-stage small cell lung cancer (ES-SCLC) admitted to Tianjin Medical University Cancer Institute & Hospital in May 2022. The patient was initially diagnosed with stage Ⅳextensive-stage small cell lung cancer, with liver and brain metastases. First-line treatment consisted of four cycles of durvalumab in combination with chemotherapy. Imaging indicated significant regression of the lung lesions and a marked reduction in the brain and liver metastases, achieving a near-complete response. During durvalumab monotherapy, the patient developed multiple oligoprogressions in the brain, adrenal glands, nasopharynx, oropharynx, and regional lymph nodes. Subsequent local radiotherapy, guided by the MDT discussion, effectively controlled the new metastatic lesions. Throughout this process, the primary lung and liver lesions remained stable, and no treatment-related adverse reactions were observed.Follow-up up to May 2025, the patient's overall survival has reached 36 months. This case represents long-term survival achieved through the combination of immunotherapy and local treatment.